LeoPatrizi Shares of Halozyme Therapeutics ( NASDAQ: HALO ) trended lower on Thursday after J.P. Morgan downgraded the developer of Enhanze drug delivery technology to neutral from overweight, arguing that the stock is fully valued at current levels.
However, analyst Jessica Fye raised her price.